AbbVie is the latest large pharma to join in the race to develop molecular glue degraders, while it marks Neomorph’s third major deal worth more than $1bn in just under a year.
Who: AbbVie and Neomorph
What: The two companies have signed a collaboration and option-to-license deal to develop molecular glue degraders in oncology and immunology.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The French drugmaker is expanding its neurology activities with the $470m deal.
Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.
Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.
The gene-editing company is making a deal with RNA interference-focused Sirius, but still focusing on cardiovascular disease, a major area of its pipeline.
Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.
Restructuring Edition: Prime Medicine ended its sole clinical-stage program to prioritize preclinical and partnered programs, cutting 25% of its workforce to extend its cash runway. Meanwhile, earnings season brought workforce reductions at Kyverna, Allogene, Leap and others.
The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.
